Review



mmp3  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Elabscience Biotechnology mmp3
    Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, <t>MMP3,</t> and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.
    Mmp3, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metalloproteinase+3/pmc13028745-257-4-7?v=Elabscience+Biotechnology
    Average 94 stars, based on 6 article reviews
    mmp3 - by Bioz Stars, 2026-08
    94/100 stars

    Images

    1) Product Images from "Biluo Qianyuan Formula Ameliorates Post-Traumatic Osteoarthritis by Suppressing FN1-Mediated Synovial Inflammation and Restoring Joint Homeostasis"

    Article Title: Biluo Qianyuan Formula Ameliorates Post-Traumatic Osteoarthritis by Suppressing FN1-Mediated Synovial Inflammation and Restoring Joint Homeostasis

    Journal: Pharmaceuticals

    doi: 10.3390/ph19030500

    Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, MMP3, and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.
    Figure Legend Snippet: Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, MMP3, and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.

    Techniques Used: Generated, Functional Assay, Protein-Protein interactions, Binding Assay

    BLQYF attenuates systemic inflammation and FN1-associated responses in PTOA. ( A ) Serum levels of MMP3, TGF-β, and FN1 in sham, PTOA, and PTOA mice treated with BLQYF or celecoxib. ( B ) Representative morphology and vimentin immunofluorescence staining of primary fibroblast-like synoviocytes (FLSs) isolated from synovial tissues of patients with post-traumatic osteoarthritis. Nuclei were counterstained with DAPI. Scale bar = 20 μm. ( C ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 mRNA expression in FLSs from PTOA patients and mesenchymal stem cells (MSCs) from non-osteoarthritic hip arthroplasty donors. ( D ) CCK-8 assay showing MSC viability following BLQYF treatment (0–80 ng/mL, 24 h). ( E ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 expression in FLSs following FN1 knockdown and BLQYF treatment (5, 10, 20 ng/mL, 24 h). Data were presented as mean ± SEM. Statistical significance was determined by one-way ANOVA with appropriate post hoc tests. p < 0.05, p < 0.01, p < 0.001.
    Figure Legend Snippet: BLQYF attenuates systemic inflammation and FN1-associated responses in PTOA. ( A ) Serum levels of MMP3, TGF-β, and FN1 in sham, PTOA, and PTOA mice treated with BLQYF or celecoxib. ( B ) Representative morphology and vimentin immunofluorescence staining of primary fibroblast-like synoviocytes (FLSs) isolated from synovial tissues of patients with post-traumatic osteoarthritis. Nuclei were counterstained with DAPI. Scale bar = 20 μm. ( C ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 mRNA expression in FLSs from PTOA patients and mesenchymal stem cells (MSCs) from non-osteoarthritic hip arthroplasty donors. ( D ) CCK-8 assay showing MSC viability following BLQYF treatment (0–80 ng/mL, 24 h). ( E ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 expression in FLSs following FN1 knockdown and BLQYF treatment (5, 10, 20 ng/mL, 24 h). Data were presented as mean ± SEM. Statistical significance was determined by one-way ANOVA with appropriate post hoc tests. p < 0.05, p < 0.01, p < 0.001.

    Techniques Used: Immunofluorescence, Staining, Isolation, Quantitative RT-PCR, Expressing, CCK-8 Assay, Knockdown



    Similar Products

    matrix metalloproteinase 3 antibody / mmp3  (NSJ Bioreagents)
    99
    NSJ Bioreagents matrix metalloproteinase 3 antibody / mmp3
    Matrix Metalloproteinase 3 Antibody / Mmp3, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metalloproteinase+3/custom%40v7960%4042411279?v=NSJ+Bioreagents
    Average 99 stars, based on 1 article reviews
    matrix metalloproteinase 3 antibody / mmp3 - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    mmp3  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology mmp3
    Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, <t>MMP3,</t> and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.
    Mmp3, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metalloproteinase+3/pmc13028745-257-4-7?v=Elabscience+Biotechnology
    Average 94 stars, based on 1 article reviews
    mmp3 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    matrix metalloproteinase 3  (Elabscience Biotechnology)
    94
    Elabscience Biotechnology matrix metalloproteinase 3
    Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, <t>MMP3,</t> and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.
    Matrix Metalloproteinase 3, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metalloproteinase+3/pm41820893-142-5-12?v=Elabscience+Biotechnology
    Average 94 stars, based on 1 article reviews
    matrix metalloproteinase 3 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    matrix metalloproteinase 3  (Proteintech)
    96
    Proteintech matrix metalloproteinase 3
    Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, <t>MMP3,</t> and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.
    Matrix Metalloproteinase 3, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/matrix+metalloproteinase+3/pmc13013296-150-27-64?v=Proteintech
    Average 96 stars, based on 1 article reviews
    matrix metalloproteinase 3 - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, MMP3, and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.

    Journal: Pharmaceuticals

    Article Title: Biluo Qianyuan Formula Ameliorates Post-Traumatic Osteoarthritis by Suppressing FN1-Mediated Synovial Inflammation and Restoring Joint Homeostasis

    doi: 10.3390/ph19030500

    Figure Lengend Snippet: Integrated network pharmacology and molecular docking analysis of candidate compounds and targets. ( A ) A Venn diagram illustrates the intersection of differentially expressed genes from the GSE178557 dataset with disease-related genes from GeneCards and drug-target genes from DrugBank. ( B ) The PPI network of overlapping targets was generated to visualize functional associations. Central nodes (red) indicate core hub genes identified based on degree centrality and connectivity. ( C ) A Sankey diagram correlates specific target genes ( left ) with their respective enriched KEGG biological pathways ( right ). Connectivity indicates involvement in signaling cascades such as the AGE-RAGE, TGF-beta, and IL-17 signaling pathways. ( D ) Representative 3D docking poses demonstrate the binding orientations and intermolecular interactions between active compounds (bavachinin, hederagenin, and myricanone) and primary protein targets (FN1, MMP3, and TGF-β). ( E ) A heatmap displays the molecular docking scores (binding energy, kcal/mol) for the interaction between candidate compounds and hub targets. Color intensity and numerical values represent the predicted binding stability.

    Article Snippet: The serum concentrations of MMP3 (Cat# E-EL-M0626, Elabscience Biotechnology Co., Ltd., Wuhan, China), TGF-β (Cat# E-EL-M0051, Elabscience Biotechnology Co., Ltd., Wuhan, China), and FN1 (Cat# KE00039, Elabscience Biotechnology Co., Ltd., Wuhan, China) were quantified by ELISA using commercial kits according to the manufacturers’ instructions.

    Techniques: Generated, Functional Assay, Protein-Protein interactions, Binding Assay

    BLQYF attenuates systemic inflammation and FN1-associated responses in PTOA. ( A ) Serum levels of MMP3, TGF-β, and FN1 in sham, PTOA, and PTOA mice treated with BLQYF or celecoxib. ( B ) Representative morphology and vimentin immunofluorescence staining of primary fibroblast-like synoviocytes (FLSs) isolated from synovial tissues of patients with post-traumatic osteoarthritis. Nuclei were counterstained with DAPI. Scale bar = 20 μm. ( C ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 mRNA expression in FLSs from PTOA patients and mesenchymal stem cells (MSCs) from non-osteoarthritic hip arthroplasty donors. ( D ) CCK-8 assay showing MSC viability following BLQYF treatment (0–80 ng/mL, 24 h). ( E ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 expression in FLSs following FN1 knockdown and BLQYF treatment (5, 10, 20 ng/mL, 24 h). Data were presented as mean ± SEM. Statistical significance was determined by one-way ANOVA with appropriate post hoc tests. p < 0.05, p < 0.01, p < 0.001.

    Journal: Pharmaceuticals

    Article Title: Biluo Qianyuan Formula Ameliorates Post-Traumatic Osteoarthritis by Suppressing FN1-Mediated Synovial Inflammation and Restoring Joint Homeostasis

    doi: 10.3390/ph19030500

    Figure Lengend Snippet: BLQYF attenuates systemic inflammation and FN1-associated responses in PTOA. ( A ) Serum levels of MMP3, TGF-β, and FN1 in sham, PTOA, and PTOA mice treated with BLQYF or celecoxib. ( B ) Representative morphology and vimentin immunofluorescence staining of primary fibroblast-like synoviocytes (FLSs) isolated from synovial tissues of patients with post-traumatic osteoarthritis. Nuclei were counterstained with DAPI. Scale bar = 20 μm. ( C ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 mRNA expression in FLSs from PTOA patients and mesenchymal stem cells (MSCs) from non-osteoarthritic hip arthroplasty donors. ( D ) CCK-8 assay showing MSC viability following BLQYF treatment (0–80 ng/mL, 24 h). ( E ) qRT–PCR analysis of MMP3 , TGF-β , and FN1 expression in FLSs following FN1 knockdown and BLQYF treatment (5, 10, 20 ng/mL, 24 h). Data were presented as mean ± SEM. Statistical significance was determined by one-way ANOVA with appropriate post hoc tests. p < 0.05, p < 0.01, p < 0.001.

    Article Snippet: The serum concentrations of MMP3 (Cat# E-EL-M0626, Elabscience Biotechnology Co., Ltd., Wuhan, China), TGF-β (Cat# E-EL-M0051, Elabscience Biotechnology Co., Ltd., Wuhan, China), and FN1 (Cat# KE00039, Elabscience Biotechnology Co., Ltd., Wuhan, China) were quantified by ELISA using commercial kits according to the manufacturers’ instructions.

    Techniques: Immunofluorescence, Staining, Isolation, Quantitative RT-PCR, Expressing, CCK-8 Assay, Knockdown